13 Best Low Risk High Growth Stocks to Buy

Page 2 of 11

10. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Beta: 0.84

EPS next 5Y: 25.93%

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) made its way to our list of 13 best low risk high growth stocks to buy. Mixed analysts’ sentiments for the stock, following the presentation of preclinical data for BP1.15205.

Headquartered in New Jersey, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company engaged in the process of developing therapies for rare neurological and sleep disorders. The company’s lead product, WAKIX® (pitolisant), treats excessive daytime sleepiness in narcolepsy, with additional pipeline treatments for Prader‑Willi Syndrome and myotonic dystrophy.

On June 11, 2025, the company announced new preclinical data for BP1.15205. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) claimed that this unique chemical scaffold is a potential best-in-class orexin-2 agonist. The company’s data indicates BP1.15205 has notable wake-promoting and cataplexy-suppressing effects in narcolepsy type-1 mouse models. With plans to initiate human trials in the later part of 2025, the company strengthens its foothold in the sleep-wake disorder treatment market, with BP1.15205.

Following this announcement, Mizuho Securities and H.C. Wainwright maintained their Buy rating on the stock. Deutsche Bank also keeps a Buy rating for the stock while raising the price target from $54 to $55. Goldman Sachs, however, sticks to their Hold rating on the company.

Amid these mixed ratings, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) maintains its position as a low-risk stock with high growth potential by offering a beta of 0.84 with an EPS growth of 25.93% for the next five years.

Page 2 of 11